BioPharmSignal logoBioPharmSignal

Biotech News

Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)

Terns Pharmaceuticals (TERN)Terns PharmaceuticalsClinical readout

Terns’ lead candidate TERN-701 is an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor c urrently in Phase 1/2 development for certain patients with CML Merck to hold investor call at 8 a.m. EDT today RAHWAY, N.J. and FOSTER CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Merck

Related news

LXRXLexicon Pharmaceuticals2026-08-24 12:30 EST

Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851

LXRXLexicon Pharmaceuticals2026-07-27 12:30 EST

Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)

TEVATeva Pharmaceutical Industries2026-09-02 11:03 EST

Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential

RYTMRhythm Pharmaceuticals2026-08-04 10:55 EST

Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity

RVMDRevolution Medicines2026-09-02 21:50 EST

New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer

MNKDMannKind2026-07-29 10:30 EST

MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF

LYELLyell Immunopharma2026-09-10 20:05 EST

Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer

IDYAIDEAYA Biosciences2026-09-09 10:00 EST

IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma

GSKGSK plc2026-07-28 12:00 EST

GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026

TEVATeva Pharmaceutical Industries2026-09-18 20:30 EST

Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults

View all latest news

Terns Pharmaceuticals

Terns Pharmaceuticals is a small-molecule biotech focused on oncology and metabolic disease opportunities. Its pipeline is built around targeted therapies with room for multiple shots on goal.

Recent company news

TERNTerns Pharmaceuticals2026-04-27 12:05 EST

Terns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid Leukemia

TERNTerns Pharmaceuticals2026-04-02 20:05 EST

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

TERNTerns Pharmaceuticals2026-03-25 10:48 EST

Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)

TERNTerns Pharmaceuticals2026-02-25 21:05 EST

Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences

TERNTerns Pharmaceuticals2026-01-07 21:05 EST

Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference

Stock data

Close
52.95 USD
Market cap
6.12B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States